PEPG
PepGen Inc. NASDAQ Listed May 6, 2022$2.29
-5.57%
vs $2.42
Mkt Cap $158.1M
52w Low $1.31
15.0% of range
52w High $7.80
50d MA $2.71
200d MA $3.42
P/E (TTM)
—
EV/EBITDA
—
P/B
0.7x
Debt/Equity
0.1x
ROE
-60.8%
P/FCF
-1.2x
RSI (14)
25.00
ATR (14)
$0.17
Beta
2.34
50d MA
$2.71
200d MA
$3.42
Avg Volume
789.3K
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
245 Main Street · Boston, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | AMC | -0.28 | -0.26 | +8.6% | 2.41 | +2.9% | +18.3% | +4.9% | -3.0% | +0.0% | +2.8% | — |
| May 12, 2026 | AMC | -0.31 | -0.26 | +16.1% | 1.68 | -3.0% | +6.0% | -7.3% | -6.1% | -5.2% | -6.1% | — |
| Mar 4, 2026 | AMC | -0.40 | -0.27 | +32.5% | 6.76 | -18.5% | -18.5% | +3.3% | -2.1% | +10.6% | +2.1% | — |
| Nov 12, 2025 | AMC | -0.63 | -0.52 | +17.5% | 5.13 | -1.4% | -4.7% | -3.1% | +12.9% | +7.3% | -3.7% | — |
| Aug 7, 2025 | AMC | -0.85 | -0.70 | +17.6% | 1.19 | -0.8% | -10.1% | -5.6% | +12.9% | -0.9% | +14.2% | — |
| May 8, 2025 | AMC | -0.72 | -0.92 | -27.8% | 1.54 | -1.3% | -2.6% | +0.7% | +1.3% | -9.8% | +3.6% | — |
| Feb 24, 2025 | AMC | -0.81 | -0.68 | +16.0% | 2.29 | +3.1% | -25.3% | -10.5% | +58.8% | +29.6% | -10.8% | — |
| Nov 7, 2024 | AMC | -0.87 | -0.66 | +24.1% | 5.63 | -3.0% | -11.0% | -0.4% | -9.0% | +0.2% | -1.3% | — |
| Aug 8, 2024 | AMC | -0.72 | -0.87 | -20.8% | 8.98 | +1.1% | -4.3% | +0.3% | -10.1% | +7.5% | +8.9% | — |
| May 14, 2024 | AMC | -0.74 | -0.63 | +14.9% | 13.99 | +2.6% | -1.2% | -1.2% | -3.6% | +2.5% | +3.0% | — |
| Mar 6, 2024 | AMC | -1.01 | -0.82 | +18.8% | 15.41 | -1.4% | -8.0% | +0.4% | -0.8% | -1.7% | -1.0% | — |
| Nov 8, 2023 | AMC | -0.88 | -0.98 | -11.4% | 4.48 | -2.9% | -9.2% | -5.2% | +12.4% | -0.9% | -1.4% | — |
| Aug 8, 2023 | AMC | -0.81 | -0.82 | -1.2% | 5.13 | +0.0% | +2.5% | +0.8% | +5.3% | -0.7% | +6.0% | — |
| May 11, 2023 | AMC | -0.79 | -0.69 | +12.7% | 14.24 | +1.9% | +3.2% | +2.0% | -3.3% | +0.1% | +3.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 16 | Craig Hallum | Initiates | Buy | $11 | $1.53 | $1.63 | +6.5% | +3.9% | +6.9% | +5.3% | +2.2% | -0.5% |
| Apr 1 | Wedbush | Maintains | Outperform → Outperform | — | $1.77 | $1.81 | +2.3% | -1.7% | -0.6% | +5.2% | -8.2% | -0.6% |
| Mar 31 | Wedbush | Maintains | Outperform → Outperform | — | $4.23 | $2.01 | -52.5% | -58.2% | -1.7% | -0.6% | +5.2% | -8.2% |
| Feb 18 | Guggenheim | Maintains | Buy → Buy | — | $6.79 | $6.77 | -0.3% | -3.7% | +1.8% | -6.6% | +1.9% | -0.3% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.13 | $5.06 | -1.4% | -4.7% | -3.1% | +12.9% | +7.3% | -3.7% |
| Oct 27 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.57 | $5.31 | +16.2% | +18.8% | -8.3% | -9.4% | +0.4% | +2.9% |
| Sep 30 | Wedbush | Maintains | Outperform → Outperform | — | $4.64 | $4.50 | -3.0% | -0.4% | +1.9% | +7.9% | +1.0% | -3.3% |
| Sep 25 | Wedbush | Maintains | Outperform → Outperform | — | $2.66 | $5.90 | +121.8% | +121.1% | -13.8% | -8.5% | -0.4% | +1.9% |
| Sep 25 | Stifel | Maintains | Buy → Buy | — | $2.66 | $5.90 | +121.8% | +121.1% | -13.8% | -8.5% | -0.4% | +1.9% |
| Sep 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.66 | $5.90 | +121.8% | +121.1% | -13.8% | -8.5% | -0.4% | +1.9% |
| Sep 24 | Guggenheim | Maintains | Buy → Buy | — | $1.95 | $1.95 | +0.0% | +36.4% | +121.1% | -13.8% | -8.5% | -0.4% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.58 | $1.57 | -0.6% | +5.7% | -12.6% | -1.4% | +6.2% | -1.3% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.54 | $1.52 | -1.3% | -2.6% | +0.7% | +1.3% | -9.8% | +3.6% |
| Feb 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.37 | $2.61 | +90.5% | +67.2% | -25.3% | -10.5% | +58.8% | +29.6% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.84 | $1.81 | -1.6% | -21.7% | -10.4% | -3.1% | +0.0% | +7.2% |
| Dec 16 | BofA Securities | Downgrade | Neutral → Underperform | — | $4.68 | $2.90 | -38.0% | -3.6% | -4.7% | -5.6% | +0.7% | -11.2% |
| Nov 18 | BofA Securities | Maintains | Neutral → Neutral | — | $4.12 | $4.20 | +1.9% | +0.2% | +8.2% | -1.6% | -1.8% | +2.1% |
| Nov 8 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.63 | $5.46 | -3.0% | -11.0% | -0.4% | -9.0% | +0.2% | -1.3% |
| Nov 8 | Wedbush | Maintains | Outperform → Outperform | — | $5.63 | $5.46 | -3.0% | -11.0% | -0.4% | -9.0% | +0.2% | -1.3% |
| Aug 1 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.43 | $11.16 | -2.4% | -11.9% | -2.6% | -5.5% | +1.3% | -5.4% |
| Jul 31 | Wedbush | Maintains | Outperform → Outperform | — | $16.98 | $10.26 | -39.6% | -32.7% | -11.9% | -2.6% | -5.5% | +1.3% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.99 | $14.36 | +2.6% | -1.2% | -1.2% | -3.6% | +2.5% | +3.0% |
| May 15 | Wedbush | Maintains | Outperform → Outperform | — | $13.99 | $14.36 | +2.6% | -1.2% | -1.2% | -3.6% | +2.5% | +3.0% |
| Mar 7 | Wedbush | Maintains | Outperform → Outperform | — | $15.41 | $15.20 | -1.4% | -8.0% | +0.4% | -0.8% | -1.7% | -1.0% |
| Jan 30 | Wedbush | Maintains | Outperform → Outperform | — | $7.25 | $7.49 | +3.3% | +50.8% | -8.2% | +23.5% | -5.9% | -8.8% |
| Sep 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.03 | $5.98 | -0.8% | +4.6% | +1.1% | -3.8% | +3.1% | -4.9% |
| Aug 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.13 | $5.13 | +0.0% | +2.5% | +0.8% | +5.3% | -0.7% | +6.0% |
| Jun 14 | Wedbush | Maintains | Outperform → Outperform | — | $13.26 | $12.87 | -2.9% | -8.0% | +5.8% | -5.3% | -17.3% | -8.6% |
| Jun 14 | Stifel | Maintains | Buy → Buy | — | $13.26 | $12.87 | -2.9% | -8.0% | +5.8% | -5.3% | -17.3% | -8.6% |
| May 31 | Wedbush | Maintains | Outperform → Outperform | — | $15.78 | $14.33 | -9.2% | -5.1% | -1.5% | +9.4% | -2.9% | +3.8% |
| May 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.24 | $14.51 | +1.9% | +3.2% | +2.0% | -3.3% | +0.1% | +3.0% |
| Mar 24 | Wedbush | Maintains | Outperform → Outperform | — | $16.88 | $20.00 | +18.5% | -9.8% | -16.2% | -9.9% | -0.5% | +3.8% |
| Nov 10 | SVB Leerink | Maintains | Outperform → Outperform | — | $11.07 | $11.25 | +1.6% | +12.9% | +6.6% | +8.3% | -0.1% | +4.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 | Kasraian Kasra | Chief Technical Officer | Sell | 1,233 | $1.41 | $2K | 50,074 | -0.65% | -1.36% |
8-K · 7.01
! Medium
PepGen Inc. -- 8-K 7.01: Regulation FD Disclosure
May 21
8-K · 2.02
!! High
PepGen Inc. -- 8-K 2.02: Earnings Results
May 12
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
PEPG announced positive clinical data from an oligonucleotide therapy trial, potentially advancing its pipeline for severe neuromuscular and neurological diseases and validating its therapeutic approach.
Mar 30
8-K · 8.01
!! High
PepGen Inc. -- 8-K 8.01: Material Event / Announcement
PepGen's experimental myotonic dystrophy treatment PGN-EDODM1 faces a partial clinical hold from the FDA, restricting the ongoing Phase 2 trial and likely delaying development progress.
Mar 4
8-K · 7.01
! Medium
PepGen Inc. -- 8-K 7.01: Regulation FD Disclosure
PepGen Inc. disclosed information via Form 8-K that it explicitly states should not be interpreted as an admission of materiality, potentially limiting investor reliance on the disclosed details.
Mar 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 2,168,800 | $14M | Added | Dec 2025 |
| 2 | Laurion Capital Management Lp | 2,052,133 | $13M | Added | Dec 2025 |
| 3 | Viking Global Investors Lp | 3,482,434 | $6M | — | Jun 2026 |
| 4 | Vivo Capital, Llc | 2,325,000 | $4M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,935,920 | $3M | — | Jun 2026 |
| 6 | Millennium Management Llc | 1,786,765 | $3M | Reduced | Jun 2026 |
| 7 | Adar1 Capital Management, Llc | 1,607,638 | $3M | New | Mar 2026 |
| 8 | Renaissance Technologies Llc | 1,520,246 | $3M | Added | Jun 2026 |
| 9 | Citadel Advisors Llc | 1,316,762 | $2M | Added | Jun 2026 |
| 10 | Blackrock, Inc. | 1,304,262 | $2M | New | Jun 2026 |
| 11 | Woodline Partners Lp | 1,311,021 | $2M | — | Mar 2026 |
| 12 | Jane Street Group, Llc | 192,733 | $1M | New | Dec 2025 |
| 13 | Qube Research & Technologies Ltd | 706,472 | $1M | Added | Mar 2026 |
| 14 | Boxer Capital Management, Llc | 250,000 | $1M | New | Sep 2025 |
| 15 | Monimus Capital Management, Lp | 138,398 | $901K | Added | Dec 2025 |
| 16 | Susquehanna International Group, Llp | 442,168 | $783K | Added | Mar 2026 |
| 17 | Marshall Wace, Llp | 298,568 | $528K | Added | Mar 2026 |
| 18 | Hudson Bay Capital Management Lp | 69,391 | $452K | New | Dec 2025 |
| 19 | Rbf Capital, Llc | 190,084 | $336K | — | Mar 2026 |
| 20 | Connor, Clark & Lunn Investment Management Ltd. | 112,071 | $202K | Added | Jun 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$158.1M
Enterprise Value
-$32.5M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.12x
P/B
0.65x
P/S
—
P/FCF
-1.25x
EV/EBITDA
—
Shares Out
42.2M
Financials (TTM)
Revenue
$0
Net Income
-$71.9M
EBITDA
-$67.8M
Free Cash Flow
-$81.9M
Op Cash Flow
-$81.6M
EPS Basic
$-2.12
EPS Diluted
$-1.50
EPS Forward
$-1.15
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$173.9M
Total Liab.
$26.5M
Total Equity
$147.4M
Cash
$148.5M
LT Debt
$13.8M
Book Value/Sh
$3.49
Debt/Equity
0.12x
Current Ratio
11.94
Quick Ratio
11.94
Returns & Growth
ROE
-60.8%
ROA
-51.5%
ROIC
-56.9%
Rev Growth YoY
+0.0%
EPS Growth YoY
+25.6%
Price Returns
2W
-16.6%
1M
-22.4%
3M
+33.7%
6M
+39.1%
12M
-48.6%
Technicals
52W High
$7.80
52W Low
$1.31
50d MA
$2.71
200d MA
$3.42
RSI (14)
25.00
ATR (14)
$0.17
Beta
2.34
Avg Volume
789K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$7.00
High
$7.00
Low
$7.00
Median
$7.00
Data updated apr 26, 2026 7:15pm
· Source: financialmodelingprep.com